IL17A and metabolic dysfunction-associated steatotic liver disease: Since no differences in plasma levels of this interleukin have been reported between NAFLD patients and control subjects thus far, interest in IL-17 as a peripheral biomarker to diagnose or stratify NAFLD has decreased.